🩺What is Cortical Cataract?
The LOCS III (Lens Opacities Classification System III) was developed by Chylack et al. (1993) at Harvard Medical School and published in Archives of Ophthalmology. It succeeded earlier LOCS I and LOCS II systems, providing improved inter-grader reliability and finer gradations. LOCS III uses standardized color slit-lamp and retroillumination photographs as reference standards for grading. The system grades three types of cataract independently: Nuclear sclerosis (opacification of the central lens nucleus) — graded from 0-5 based on increased nuclear yellowing/brunescence and opalescence on slit-lamp examination. Cortical cataract (opacification of the lens cortex) — graded from 0-5 based on the circumferential extent of cortical spokes/opacities on retroillumination. Posterior subcapsular cataract (PSC — opacification at the posterior lens capsule) — graded from 0-5 based on the area of involvement on retroillumination. The LOCS III is the most widely used cataract grading system in clinical research and has been validated against other measures of visual function including contrast sensitivity and glare disability, not only visual acuity.
📊Clinical Assessment & Risk Scoring
Healthcare professionals use these validated clinical calculators, diagnostic scales, and risk scoring systems to assess the severity, prognosis, or therapeutic dosing requirements for Cortical Cataract:
Cataract Grading — LOCS III Classification
The Lens Opacities Classification System III (LOCS III) is a standardized, validated system for grading cataract severity. It provides separate grades for nuclear sclerosis, cortical cataract, and posterior subcapsular cataract on a 0-5 scale.
🧬Diagnostic Logic & Scoring Breakdown
Each cataract type is graded independently on a 0-5 scale. Nuclear grade: 0 = clear lens, 1 = mild nuclear opalescence, 2 = moderate nuclear yellowing/opalescence, 3 = obvious nuclear brunescence, 4 = advanced nuclear brunescence, 5 = very advanced nuclear opacity/cataract. Cortical grade: 0 = no cortical opacities, 1 = minimal cortical spokes (<5%), 2 = moderate cortical involvement (5-25%), 3 = significant involvement (25-50%), 4 = extensive involvement (50-75%), 5 = very extensive involvement (>75%). PSC grade: 0 = no posterior subcapsular opacity, 1 = minimal PSC (<5% of posterior capsule), 2 = moderate PSC area, 3 = significant PSC, 4 = extensive PSC, 5 = very extensive PSC. The overall cataract severity is usually determined by the highest grade among the three types. Surgical decision-making also incorporates visual acuity, visual function questionnaire, glare testing, and patient-reported visual disability.
📢Clinical Significance & Implications
Cataract is the leading cause of reversible blindness worldwide, affecting over 95 million people globally. The LOCS III grading system is the standard for: (1) Clinical documentation — standardized terminology for describing cataract type and severity in medical records. (2) Surgical decision-making — grades ≥3 are typically associated with visual function impairment warranting surgical consideration, though patient-reported symptoms and visual needs are equally important. (3) Surgical planning — nuclear grade affects phacoemulsification energy requirements and may influence IOL power calculation formulas. (4) Research — LOCS III is the standard classification for clinical trials on cataract prevention (e.g., AREDS, vitamin studies). (5) Medico-legal — provides objective documentation of pre-operative cataract severity. Correlation with visual acuity is moderate — some patients with grade 3-4 cataracts maintain 20/40 vision while others with grade 2 have significant glare disability, underscoring the need for functional assessment alongside morphological grading.
💡 Clinical Assessment Scenario Example
An 78-year-old male presents with decreased vision over 2 years. Slit-lamp examination: Nuclear sclerosis grade 4/5 with advanced brunescence, cortical cataract grade 1/5 with minimal inferior cortical spokes, PSC grade 1/5 with small central posterior opacity. LOCS III: N4 C1 PSC1. Overall severity: Grade 4 (severe, nuclear dominant). Visual acuity 20/80. Recommendation: Cataract surgery — phacoemulsification with IOL implantation. Pre-operative biometry, corneal topography, and medical clearance.
💊Common Medications & Interventions
The following pharmacological therapies and substances are commonly referenced or adjusted based on the clinical assessment of Cortical Cataract:
⚠️Clinical Assessment Pitfalls
❌ Mistake: Using LOCS III grades without considering cataract morphology
✅ Correction: The grade should reflect the specific cataract morphology, not just visual acuity. A patient with 20/200 vision from PSC may have a PSC grade of 5 but nuclear grade of 0. Grade based on slit-lamp appearance, not vision level.
🚑When to Seek Medical Attention
This reference supports clinical assessment of Cortical Cataract; it does not replace urgent evaluation. Seek prompt in-person medical care if symptoms are severe, rapidly worsening, or life-threatening, or if you are unsure about a diagnosis or treatment plan. Patients should always consult their physician before starting or changing any therapy.
❓Frequently Asked Questions
Q: At what LOCS III grade should cataract surgery be considered?
Surgery is typically considered when the cataract is grade ≥3 in any category AND the patient has visual symptoms that affect quality of life or visual function (e.g., activity limitation, glare, decreased contrast sensitivity, difficulty driving at night). The decision is not based on grade alone but on a combination of morphological severity, visual acuity, visual function measurements, and patient-reported disability.
Q: How often should cataract grading be done?
For patients being monitored before surgery, grading should be updated every 6-12 months. Progression rates vary: nuclear cataracts typically progress slowly (0.1-0.3 grade/year), while PSC can progress more rapidly (0.2-0.7 grade/year). Patients with rapid progression may warrant endocrinology workup for underlying causes (diabetes, corticosteroid use, uveitis).
📚Evidence-Based References
Medically Reviewed By
Dr. Mahmoud El-Sayed
MD, Ophthalmology | Ophthalmology
Dr. Mahmoud El-Sayed is a consultant ophthalmologist with over 15 years of experience in anterior segment surgery and cataract surgery.